AngioDynamics (UG2) Stock Overview
A medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
UG2 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
AngioDynamics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.25 |
| 52 Week High | US$13.20 |
| 52 Week Low | US$7.00 |
| Beta | 0.43 |
| 1 Month Change | 3.35% |
| 3 Month Change | 3.35% |
| 1 Year Change | 17.83% |
| 3 Year Change | 15.63% |
| 5 Year Change | -52.07% |
| Change since IPO | -14.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| UG2 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -1.6% | -1.3% | 0.07% |
| 1Y | 17.8% | -28.7% | 1.1% |
Return vs Industry: UG2 exceeded the German Medical Equipment industry which returned -28.7% over the past year.
Return vs Market: UG2 exceeded the German Market which returned 1.1% over the past year.
Price Volatility
| UG2 volatility | |
|---|---|
| UG2 Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: UG2 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: UG2's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 675 | Jim Clemmer | www.angiodynamics.com |
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company’s thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers’ off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage.
AngioDynamics, Inc. Fundamentals Summary
| UG2 fundamental statistics | |
|---|---|
| Market cap | €396.61m |
| Earnings (TTM) | -€26.76m |
| Revenue (TTM) | €267.48m |
Is UG2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UG2 income statement (TTM) | |
|---|---|
| Revenue | US$313.73m |
| Cost of Revenue | US$143.39m |
| Gross Profit | US$170.34m |
| Other Expenses | US$201.72m |
| Earnings | -US$31.39m |
Last Reported Earnings
Feb 28, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 54.30% |
| Net Profit Margin | -10.00% |
| Debt/Equity Ratio | 3.4% |
How did UG2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/04 09:53 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2026/02/28 |
| Annual Earnings | 2025/05/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AngioDynamics, Inc. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Taylor | Barclays |
| John Young | Canaccord Genuity |
| William Plovanic | Canaccord Genuity |